New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus
The Lupus Research Alliance welcomes new results from the Phase 2 part of the AMETHYST Phase 2/3 study, showing that the...
litifilimab
Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus
Decision Could Speed Up Treatment Approval for Skin-Related Lupus Manifestation The Lupus Research Alliance applauds the decision by...
New England Journal of Medicine Publishes Positive Data of Litifilimab in Cutaneous Lupus Erythematosus
August, 2022
We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England...